MC5R and cancer: Direct administration of inhibitory antibody, polypeptide antagonist, or small molecule negative allosteric modulator of MC5R might improve cancer therapies through PD1/PDL1, CTLA4, or chimeric antigen receptor T (CAR-T) cells.